

NOTICE: COVERAGE DISCONTINUATION FOR SELECT TERSERA THERAPEUTICS MEDICATIONS

April 3, 2025

Dear Providers,

Effective **May 1, 2025**, the following medications made by TerSera will no longer be covered under the BCBSAZ Health Choice Medicaid and BCBSAZ Health Choice Pathway D-SNP plans:

- J9353 Margetuximab-cmkb (Margenza) injection
- J9202 Goserelin (Zoladex) implant
- J1201 Cetirizine (Quzyttir) injection
- J8670 Rolapitant (Varubi) oral tablets
- J8499 Telotristat (Xermelo) oral tablets
- J2278 Ziconotide (Prialt) injection

Key Information:

- **Reason for Change:** Per Social Security Law Sec. 1927 [42 U.S.C. 1396r-8] (a), the Centers for Medicare & Medicaid Services (CMS) requires drug manufacturers to participate in the Medicaid Drug Rebate Program (MDRP) for their drugs to be eligible for Medicaid coverage. The manufacturer TerSera has chosen not to participate.
- **Provider Action:** If your patient is currently using one of the affected drugs, please discuss alternative treatment options with them.

We appreciate your prompt attention to this update and your continued commitment to patient care.

To view this notice for embedded links and content specific to education-related material, please visit us online at <https://www.azblue.com/health-choice-az> under our “For Providers” tab.